Challenges in immunodiagnostic tests for leprosy.

INTRODUCTION Despite the effectiveness of multidrug therapy, leprosy still represents a significant global health problem: transmission of Mycobacterium leprae (M. leprae) is not sufficiently reduced as witnessed by unwavering new case rates in leprosy-endemic countries. Early detection of M. leprae infection (before clinical manifestations occur) is vital to reduction of transmission. Current diagnosis relies on detection of clinical signs since there are no tests available to detect asymptomatic M. leprae infection or predict progression to leprosy. AREAS COVERED Identification of risk factors (immunological or genetic biomarkers) for disease development and/or onset of leprosy reactions is imperative for efficient diagnosis. Tests simultaneously detecting biomarkers specific for cellular and humoral immunity are well suited for diagnosis of different clinical outcomes of leprosy. This review describes the challenges of discovery of biomarkers for M. leprae infection and their implementation in field-friendly tests. EXPERT OPINION In view of the complicated nature of M. leprae infections, it is essential to invest in longitudinal studies allowing intra-individual comparison of immune and genetic biomarkers in various leprosy-endemic areas. Furthermore, the effect of co-infections on biomarker profiles should also be taken into account. Diagnostic tests based on such biomarkers can contribute significantly to early detection of leprosy (reactions) thus helping reduce nerve damage.

[1]  P. Vantourout,et al.  Six-of-the-best: unique contributions of γδ T cells to immunology , 2013, Nature Reviews Immunology.

[2]  J. Spencer,et al.  PARK2 Mediates Interleukin 6 and Monocyte Chemoattractant Protein 1 Production by Human Macrophages , 2013, PLoS neglected tropical diseases.

[3]  B. Gontijo,et al.  Hansen's disease: a vanishing disease? , 2012, Memorias do Instituto Oswaldo Cruz.

[4]  P. Saunderson,et al.  Identification of serological biomarkers of infection, disease progression and treatment efficacy for leprosy. , 2012, Memorias do Instituto Oswaldo Cruz.

[5]  Sang-Nae Cho,et al.  Comparison of two rapid tests for anti-phenolic glycolipid-I serology in Brazil and Nepal. , 2012, Memorias do Instituto Oswaldo Cruz.

[6]  C. Salgado,et al.  High rates of undiagnosed leprosy and subclinical infection amongst school children in the Amazon Region. , 2012, Memórias do Instituto Oswaldo Cruz.

[7]  O. Lund,et al.  Mycobacterium leprae virulence-associated peptides are indicators of exposure to M. leprae in Brazil, Ethiopia and Nepal. , 2012, Memorias do Instituto Oswaldo Cruz.

[8]  S. Reed,et al.  Seroreactivity to new Mycobacterium leprae protein antigens in different leprosy-endemic regions in Brazil. , 2012, Memorias do Instituto Oswaldo Cruz.

[9]  A. Alcaïs,et al.  Genetics of leprosy reactions: an overview. , 2012, Memorias do Instituto Oswaldo Cruz.

[10]  V. Pascual,et al.  Detectable Changes in The Blood Transcriptome Are Present after Two Weeks of Antituberculosis Therapy , 2012, PloS one.

[11]  M. Saraya,et al.  Diabetic status of patients with leprosy in Kuwait. , 2012, Journal of infection and public health.

[12]  C. Khor,et al.  Genome-Wide Expression Profiling Identifies Type 1 Interferon Response Pathways in Active Tuberculosis , 2012, PloS one.

[13]  C. Locht,et al.  Broad heparin‐binding haemagglutinin‐specific cytokine and chemokine response in infants following Mycobacterium bovis BCG vaccination , 2012, European journal of immunology.

[14]  T. Ottenhoff.  New pathways of protective and pathological host defense to mycobacteria. , 2012, Trends in microbiology.

[15]  U. Sengupta,et al.  Increased Serum Circulatory Levels of Interleukin 17F in Type 1 Reactions of Leprosy , 2012, Journal of Clinical Immunology.

[16]  S. Reed,et al.  Evaluation of various cytokines elicited during antigen-specific recall as potential risk indicators for the differential development of leprosy , 2012, European Journal of Clinical Microbiology & Infectious Diseases.

[17]  Sang-Nae Cho,et al.  New Biomarkers with Relevance to Leprosy Diagnosis Applicable in Areas Hyperendemic for Leprosy , 2012, The Journal of Immunology.

[18]  A. Siika,et al.  Human Immunodeficiency Virus and Leprosy Coinfection: Challenges in Resource-Limited Setups , 2012, Case reports in medicine.

[19]  P. Haslett,et al.  Lessons of leprosy: the emergence of TH17 cytokines during type II reactions (ENL) is teaching us about T-cell plasticity. , 2012, Journal of drugs in dermatology : JDD.

[20]  S. Kaufmann,et al.  Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go? , 2012, PLoS pathogens.

[21]  G. Benard,et al.  Increased expression of regulatory T cells and down-regulatory molecules in lepromatous leprosy. , 2012, The American journal of tropical medicine and hygiene.

[22]  P. Brennan,et al.  Pathogen-Specific Epitopes as Epidemiological Tools for Defining the Magnitude of Mycobacterium leprae Transmission in Areas Endemic for Leprosy , 2012, PLoS neglected tropical diseases.

[23]  T. Ottenhoff,et al.  Peptides Derived from Mycobacterium leprae ML1601c Discriminate between Leprosy Patients and Healthy Endemic Controls , 2012, Journal of tropical medicine.

[24]  E. Sarno,et al.  Circulating levels of insulin-like growth factor-I (IGF-I) correlate with disease status in leprosy , 2011, BMC infectious diseases.

[25]  K. Franken,et al.  Development of a mouse food pad model for detection of sub clinical leprosy. , 2011, Leprosy review.

[26]  K. Franken,et al.  Cytokine responses to Mycobacterium leprae unique proteins differentiate between Mycobacterium leprae infected and naive armadillos. , 2011, Leprosy Review.

[27]  A. Geluk,et al.  Postgenomic Mycobacterium leprae antigens for cellular and serological diagnosis of M. leprae exposure, infection and leprosy disease. , 2011, Leprosy review.

[28]  D. Lockwood,et al.  Cytokine and Protein Markers of Leprosy Reactions in Skin and Nerves: Baseline Results for the North Indian INFIR Cohort , 2011, PLoS neglected tropical diseases.

[29]  C. Salgado,et al.  Anti-PGL-I seroepidemiology in leprosy cases: household contacts and school children from a hyperendemic municipality of the Brazilian Amazon. , 2011, Leprosy review.

[30]  P. Brennan,et al.  The role of Mycobacterium leprae phenolic glycolipid I (PGL-I) in serodiagnosis and in the pathogenesis of leprosy. , 2011, Leprosy review.

[31]  H. Tanke,et al.  Lateral flow assay for simultaneous detection of cellular- and humoral immune responses. , 2011, Clinical biochemistry.

[32]  J. Goeman,et al.  Identification of biomarkers for tuberculosis disease using a novel dual-color RT–MLPA assay , 2011, Genes and Immunity.

[33]  D. Lockwood,et al.  Leprosy now: epidemiology, progress, challenges, and research gaps. , 2011, The Lancet. Infectious diseases.

[34]  C. Massone,et al.  Leprosy and HIV coinfection: a critical approach , 2011, Expert review of anti-infective therapy.

[35]  M. Barreto,et al.  Successes and failures in the control of infectious diseases in Brazil: social and environmental context, policies, interventions, and research needs , 2011, The Lancet.

[36]  S. Reed,et al.  Specific IgG antibody responses may be used to monitor leprosy treatment efficacy and as recurrence prognostic markers , 2011, European Journal of Clinical Microbiology & Infectious Diseases.

[37]  L. Richeldi,et al.  A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis. , 2011, Tuberculosis.

[38]  Diana J L Williams,et al.  Increased CXC Ligand 10 Levels and Gene Expression in Type 1 Leprosy Reactions , 2011, Clinical and Vaccine Immunology.

[39]  T. Graeber,et al.  MicroRNA-21 targets the vitamin D-dependent antimicrobial pathway in leprosy , 2011, Nature Medicine.

[40]  S. Kaufmann,et al.  For better or for worse: the immune response against Mycobacterium tuberculosis balances pathology and protection , 2011, Immunological reviews.

[41]  L. Abel,et al.  Leprosy as a genetic disease , 2011, Mammalian Genome.

[42]  G. Ireton,et al.  Immunologically reactive M. leprae antigens with relevance to diagnosis and vaccine development , 2011, BMC infectious diseases.

[43]  P. Saunderson,et al.  Analysis of Antibody Responses to Mycobacterium leprae Phenolic Glycolipid I, Lipoarabinomannan, and Recombinant Proteins To Define Disease Subtype-Specific Antigenic Profiles in Leprosy , 2010, Clinical and Vaccine Immunology.

[44]  N. Range,et al.  Potential of interferon-&ggr;-inducible protein 10 in improving tuberculosis diagnosis in HIV-infected patients , 2010, European Respiratory Journal.

[45]  G. Kaplan,et al.  Association of TNF, MBL, and VDR polymorphisms with leprosy phenotypes. , 2010, Human immunology.

[46]  C. Massone,et al.  Leprosy and HIV coinfection: a clinical, pathological, immunological, and therapeutic study of a cohort from a Brazilian referral center for infectious diseases. , 2010, The Journal of infectious diseases.

[47]  T. Ottenhoff,et al.  LL-37 Directs Macrophage Differentiation toward Macrophages with a Proinflammatory Signature , 2010, The Journal of Immunology.

[48]  R. Dietze,et al.  Presence of intestinal helminths decreases T helper type 1 responses in tuberculoid leprosy patients and may increase the risk for multi‐bacillary leprosy , 2010, Clinical and experimental immunology.

[49]  Virginia Pascual,et al.  An Interferon-Inducible Neutrophil-Driven Blood Transcriptional Signature in Human Tuberculosis , 2010, Nature.

[50]  Alimuddin Zumla,et al.  Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice , 2010, The Lancet.

[51]  A. Sher,et al.  Cutting Edge: Caspase-1 Independent IL-1β Production Is Critical for Host Resistance to Mycobacterium tuberculosis and Does Not Require TLR Signaling In Vivo , 2010, The Journal of Immunology.

[52]  Ying Wang,et al.  Genomewide association study of leprosy. , 2009, The New England journal of medicine.

[53]  J. Kurtz,et al.  Phagocytosis mediates specificity in the immune defence of an invertebrate, the woodlouse Porcellio scaber (Crustacea: Isopoda). , 2009, Developmental and comparative immunology.

[54]  G. Cheng,et al.  Divergence of macrophage phagocytic and antimicrobial programs in leprosy. , 2009, Cell host & microbe.

[55]  D. Scollard,et al.  Potential plasma markers of type 1 and type 2 leprosy reactions: a preliminary report , 2009, BMC infectious diseases.

[56]  Gerhard Walzl,et al.  Host markers in Quantiferon supernatants differentiate active TB from latent TB infection: preliminary report , 2009, BMC pulmonary medicine.

[57]  Robert J Wilkinson,et al.  Eliminating latent tuberculosis. , 2009, Trends in microbiology.

[58]  A. Pacheco,et al.  Genetic, epidemiological and biological analysis of interleukin-10 promoter single-nucleotide polymorphisms suggests a definitive role for −819C/T in leprosy susceptibility , 2009, Genes and Immunity.

[59]  조상래,et al.  From Genome-Based In Silico Predictions to Ex Vivo Verification of Leprosy Diagnosis , 2009, Clinical and Vaccine Immunology.

[60]  G. Ireton,et al.  Selection of Antigens and Development of Prototype Tests for Point-of-Care Leprosy Diagnosis , 2008, Clinical and Vaccine Immunology.

[61]  Luiz Ricardo Goulart,et al.  Leprosy: diagnostic and control challenges for a worldwide disease , 2008, Archives of Dermatological Research.

[62]  Richard D. Wells,et al.  Human TLR1 Deficiency Is Associated with Impaired Mycobacterial Signaling and Protection from Leprosy Reversal Reaction , 2008, PLoS neglected tropical diseases.

[63]  Michel Zuiderwijk,et al.  A user-friendly, highly sensitive assay to detect the IFN-gamma secretion by T cells. , 2008, Clinical biochemistry.

[64]  J. Richardus,et al.  Leprosy strategy is about control, not eradication , 2008, The Lancet.

[65]  Annemieke Geluk,et al.  Rational Combination of Peptides Derived from Different Mycobacterium leprae Proteins Improves Sensitivity for Immunodiagnosis of M. leprae Infection , 2008, Clinical and Vaccine Immunology.

[66]  A. Aderem,et al.  Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. , 2008, The Journal of infectious diseases.

[67]  A. Iyer,et al.  Utility of measuring serum levels of anti‐PGL‐I antibody, neopterin and C‐reactive protein in monitoring leprosy patients during multi‐drug treatment and reactions , 2007, Tropical medicine & international health : TM & IH.

[68]  G. Ireton,et al.  Use of Protein Antigens for Early Serological Diagnosis of Leprosy , 2007, Clinical and Vaccine Immunology.

[69]  T. Ottenhoff,et al.  Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4 , 2007, Proceedings of the National Academy of Sciences.

[70]  A. Pacheco,et al.  HLA-DRB1*04 and DRB1*10 are associated with resistance and susceptibility, respectively, in Brazilian and Vietnamese leprosy patients , 2007, Genes and Immunity.

[71]  Meenakshi Singh,et al.  Stepwise replication identifies a low-producing lymphotoxin-α allele as a major risk factor for early-onset leprosy , 2007, Nature Genetics.

[72]  S. Cole,et al.  Towards an immunodiagnostic test for leprosy. , 2006, Microbes and infection.

[73]  T. Ottenhoff,et al.  HLA and leprosy in the pre and postgenomic eras. , 2006, Human immunology.

[74]  L. Fabbri,et al.  Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study , 2006, The Lancet.

[75]  Diana J L Williams,et al.  The Continuing Challenges of Leprosy , 2006, Clinical Microbiology Reviews.

[76]  T. Ottenhoff,et al.  Phenotypic and functional profiling of human proinflammatory type‐1 and anti‐inflammatory type‐2 macrophages in response to microbial antigens and IFN‐γ‐ and CD40L‐mediated costimulation , 2006, Journal of leukocyte biology.

[77]  S. Cole,et al.  Identification of Specific Proteins and Peptides in Mycobacterium leprae Suitable for the Selective Diagnosis of Leprosy1 , 2005, The Journal of Immunology.

[78]  T. Ottenhoff,et al.  Postgenomic Approach To Identify Novel Mycobacterium leprae Antigens with Potential To Improve Immunodiagnosis of Infection , 2005, Infection and Immunity.

[79]  Joachim Kurtz,et al.  Specific memory within innate immune systems. , 2005, Trends in immunology.

[80]  J. Richardus,et al.  A study on transmission and a trial of chemoprophylaxis in contacts of leprosy patients: design, methodology and recruitment findings of COLEP. , 2004, Leprosy review.

[81]  E. von Stebut,et al.  Macrophage inflammatory protein-1. , 2004, The international journal of biochemistry & cell biology.

[82]  P. Klatser,et al.  Prospective Study of Serological Conversion as a Risk Factor for Development of Leprosy among Household Contacts , 2004, Clinical Diagnostic Laboratory Immunology.

[83]  T. Hudson,et al.  Susceptibility to leprosy is associated with PARK2 and PACRG , 2004, Nature.

[84]  T. Ottenhoff,et al.  Immunological Crossreactivity of the Mycobacterium leprae CFP‐10 with its Homologue in Mycobacterium tuberculosis , 2004, Scandinavian journal of immunology.

[85]  A. Iwasaki.  The Importance of CD11b+ Dendritic Cells in CD4+ T Cell Activation In Vivo , 2003, The Journal of experimental medicine.

[86]  B. Rollins,et al.  Monocyte Chemoattractant Protein‐1 (CCL2) in Inflammatory Disease and Adaptive Immunity: Therapeutic Opportunities and Controversies , 2003, Microcirculation.

[87]  P. Klatser,et al.  Simple and Fast Lateral Flow Test for Classification of Leprosy Patients and Identification of Contacts with High Risk of Developing Leprosy , 2003, Journal of Clinical Microbiology.

[88]  T. Ottenhoff,et al.  Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae , 2002, Nature Genetics.

[89]  T. Ottenhoff,et al.  Identification and Characterization of the ESAT-6 Homologue of Mycobacterium leprae and T-Cell Cross-Reactivity with Mycobacterium tuberculosis , 2002, Infection and Immunity.

[90]  R. Pitchappan,et al.  A major susceptibility locus for leprosy in India maps to chromosome 10p13 , 2001, Nature Genetics.

[91]  B. Barrell,et al.  Massive gene decay in the leprosy bacillus , 2001, Nature.

[92]  R. Manandhar,et al.  A Postgenomic Approach to Identification ofMycobacterium leprae-Specific Peptides as T-Cell Reagents , 2000, Infection and Immunity.

[93]  S. V. van Beers,et al.  Patient contact is the major determinant in incident leprosy: implications for future control. , 1999, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[94]  T. Ottenhoff,et al.  Regulation of Mycobacterial Heat‐Shock Protein‐Reactive T Cells by HLA Class II Molecules: Lessons from Leprosy , 1991, Immunological reviews.

[95]  J. Convit,et al.  Learning from lesions: patterns of tissue inflammation in leprosy. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[96]  T. Ottenhoff,et al.  HLA class II immune response and suppression genes in leprosy. , 1987, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[97]  P. Brennan,et al.  Cellular and humoral immune response to a phenolic glycolipid antigen (PhenGL-I) in patients with leprosy , 1987, Journal of clinical microbiology.

[98]  R. Miller,et al.  Humans respond predominantly with IgM immunoglobulin to the species-specific glycolipid of Mycobacterium leprae. , 1984, The Journal of infectious diseases.

[99]  G. Stoner.  IMPORTANCE OF THE NEURAL PREDILECTION OF MYCOBACTERIUM LEPRÆ IN LEPROSY , 1979, The Lancet.

[100]  Ridley Ds,et al.  Classification of leprosy according to immunity. A five-group system. , 1966 .

[101]  T. Clark,et al.  Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. , 2013, The Journal of infectious diseases.

[102]  D. Lockwood,et al.  Human immunodeficiency virus and leprosy: an update. , 2011, Dermatologic clinics.

[103]  Dennis J. Montoya,et al.  Learning from leprosy: insight into the human innate immune response. , 2010, Advances in immunology.

[104]  C. Antunes,et al.  The result patterns of ML Flow and ELISA (PGL-I) serologic tests in leprosy-endemic and non-endemic areas. , 2008, Revista da Sociedade Brasileira de Medicina Tropical.

[105]  E. N. Miller,et al.  Evidence for a cluster of genes on chromosome 17q11–q21 controlling susceptibility to tuberculosis and leprosy in Brazilians , 2004, Genes and Immunity.

[106]  L. Abel,et al.  Segregation of HLA/TNF region is linked to leprosy clinical spectrum in families displaying mixed leprosy subtypes , 2003, Genes and Immunity.

[107]  G. Kaplan,et al.  Leprosy and cell-mediated immunity. , 1991, Current opinion in immunology.

[108]  B. Bloom,et al.  Genetically restricted suppressor T-cell clones derived from lepromatous leprosy lesions , 1986, Nature.